Vincristine is the first-line drug for the chemotherapy of canine transmissible venereal tumor (CTVT). Drug resistance is related to tumor cyto-morphological patterns of CTVT. There are anti-cancer properties of ivermectin, thus, a combination of ivermectin and vincristine could be an effective chemo-therapeutic treatment regimen for CTVT. Study aims, therefore, were to (1) assess the frequency of CTVT cyto-morphologies, and (2) evaluate treatment efficacy and possible adverse reactions to vincristine compared with a combination vincristine and ivermectin. Dogs (n = 41) with CTVT were characterized by tumor cyto-morphology and disease severity and of those, 20 were randomly allocated into two groups. There was a control group (G-Vin; n = 10) in which there was treatment with vincristine; and an experimental group (G-Iv/Vin; n = 10) in which there was treatment with the ivermectin/vincristine combination. Although dogs in the G-Iv/Vin group had more severe disease at the beginning of the study (P = 0.0031), the number of weeks and chemotherapy sessions until tumor remission were similar among dogs of the two groups, indicating both treatments were effective. There was a decrease in the leukocyte counts (P = 0.0020), related to neutropenia (P = 0.0371) in the G-Vin but not the G-Iv/Vin treatment group. There was no tumor resistance that developed during the study regardless of the treatment regimen used or tumor cytomorphology. In summary, the use of the vincristine/ivermectin combination was well tolerated and efficacious for CTVT treatment.

中文翻译：

---

长春新碱和伊维菌素联合化学疗法治疗具有不同细胞形态学特征的天然可传播性病的狗：前瞻性评估。

长春新碱是犬传染性性病（CTVT）化疗的一线药物。耐药性与CTVT的肿瘤细胞形态学模式有关。伊维菌素具有抗癌作用，因此，伊维菌素和长春新碱的联合使用可能是CTVT的一种有效的化学治疗方案。因此，研究目标是（1）评估CTVT细胞形态的频率，以及（2）评估与长春新碱和伊维菌素联合治疗的疗效和对长春新碱的可能不良反应。CTVT犬（n = 41）的特征在于肿瘤的细胞形态和疾病严重程度，其中20只随机分为两组。有一个对照组（G-Vin； n = 10），其中接受了长春新碱的治疗。和一个实验组（G-Iv / Vin；n = 10），其中曾用伊维菌素/长春新碱联合治疗。尽管在研究开始时，G-Iv / Vin组的狗患病更为严重（P = 0.0031），但两组狗之间直到肿瘤缓解的周数和化学疗法疗程相似，这表明两种治疗均有效。G-Vin治疗组中白细胞计数减少（P = 0.0020），与中性粒细胞减少有关（P = 0.0371），而与G-Iv / Vin治疗组无关。无论使用何种治疗方案或肿瘤细胞形态，在研究期间均未出现肿瘤耐药性。总之，长春新碱/伊维菌素联合使用对CTVT治疗具有良好的耐受性和有效性。尽管在研究开始时，G-Iv / Vin组的狗患病更为严重（P = 0.0031），但两组狗之间直到肿瘤缓解的周数和化学疗法疗程相似，这表明两种治疗均有效。G-Vin治疗组中白细胞计数减少（P = 0.0020），与中性粒细胞减少有关（P = 0.0371），而与G-Iv / Vin治疗组无关。无论使用何种治疗方案或肿瘤细胞形态，在研究期间均未出现肿瘤耐药性。总之，长春新碱/伊维菌素联合使用对CTVT治疗具有良好的耐受性和有效性。尽管在研究开始时，G-Iv / Vin组的狗患病更为严重（P = 0.0031），但两组狗之间直到肿瘤缓解的周数和化学疗法疗程相似，这表明两种治疗均有效。G-Vin治疗组中白细胞计数减少（P = 0.0020），与中性粒细胞减少有关（P = 0.0371），而与G-Iv / Vin治疗组无关。无论使用何种治疗方案或肿瘤细胞形态，在研究期间均未出现肿瘤耐药性。总之，长春新碱/伊维菌素联合使用对CTVT治疗具有良好的耐受性和有效性。G-Vin治疗组中白细胞计数减少（P = 0.0020），与中性粒细胞减少有关（P = 0.0371），而与G-Iv / Vin治疗组无关。无论使用何种治疗方案或肿瘤细胞形态，在研究期间均未出现肿瘤耐药性。总之，长春新碱/伊维菌素联合使用对CTVT治疗具有良好的耐受性和有效性。G-Vin治疗组中白细胞计数减少（P = 0.0020），与中性粒细胞减少有关（P = 0.0371），而与G-Iv / Vin治疗组无关。无论使用何种治疗方案或肿瘤细胞形态，在研究期间均未出现肿瘤耐药性。总之，长春新碱/伊维菌素联合使用对CTVT治疗具有良好的耐受性和有效性。